Bio-rad Laboratories Inc (BIO) Q3 2016 10-Q Quarterly Earnings

Short answer

Bio-rad Laboratories Inc (BIO) filed its Q3 2016 10-Q quarterly report on Nov 2, 2016 for the quarter ended Sep 30, 2016.

AI summary of MD&A and risk factor updates

Q3 revenue $508.7M, up 8.3% YoY from $470.0M
Gross margin 54.9% vs 56.1% YoY, net income margin 3.6% vs 3.7%
Best segment: Life Science revenue $178.1M, up 18.4%; Clinical Diagnostics revenue $327.1M, up 3.5%
Operating cash flow $121.3M vs $150.3M; capital expenditures $96.3M through nine months
Cash, equivalents and short-term investments $806.1M; headwinds from economic uncertainty, currency and government spending constraints

FCPA settlement: DOJ and SEC declined to extend the NPA beyond November 2, 2016, ending two-year compliance obligations
International operations: foreign subsidiaries generated 61% of net sales, increasing exposure to complex and conflicting regulations
Medical-device regulation: draft European rules and stricter Russia and China requirements may delay registrations and reduce sales
ERP implementation: third deployment may repeat prior invoicing and manufacturing disruptions affecting orders, logistics, and collections
Debt burden: $434.4 million outstanding indebtedness and $200.0 million revolving facility, with $0.8 million used for standby letters of credit

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.